NASDAQ:VKTX Viking Therapeutics - VKTX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Viking Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $15.93 +0.49 (+3.17%) (As of 03/29/2023 12:00 AM ET) Add Compare Share Share Today's Range$15.13▼$16.4050-Day Range$8.40▼$15.9352-Week Range$2.02▼$16.40Volume12.65 million shsAverage Volume3.35 million shsMarket Capitalization$1.25 billionP/E RatioN/ADividend YieldN/APrice Target$22.29 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Viking Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside62.5% Upside$25.89 Price TargetShort InterestBearish7.82% of Float Sold ShortDividend StrengthN/ASustainability-0.88Upright™ Environmental ScoreNews Sentiment0.71Based on 26 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.96) to ($1.06) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.39 out of 5 starsMedical Sector562nd out of 999 stocksPharmaceutical Preparations Industry267th out of 489 stocks 4.5 Analyst's Opinion Consensus RatingViking Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $25.89, Viking Therapeutics has a forecasted upside of 62.5% from its current price of $15.93.Amount of Analyst CoverageViking Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.82% of the float of Viking Therapeutics has been sold short.Short Interest Ratio / Days to CoverViking Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Viking Therapeutics has recently increased by 9.48%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldViking Therapeutics does not currently pay a dividend.Dividend GrowthViking Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreViking Therapeutics has received a 74.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Viking Therapeutics is -0.88. Previous Next 3.7 News and Social Media Coverage News SentimentViking Therapeutics has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 26 news articles for Viking Therapeutics this week, compared to 1 article on an average week.Search Interest55 people have searched for VKTX on MarketBeat in the last 30 days. This is an increase of 72% compared to the previous 30 days.MarketBeat Follows14 people have added Viking Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 17% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Viking Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.50% of the stock of Viking Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 34.71% of the stock of Viking Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Viking Therapeutics are expected to decrease in the coming year, from ($0.96) to ($1.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Viking Therapeutics is -17.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Viking Therapeutics is -17.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioViking Therapeutics has a P/B Ratio of 8.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Viking Therapeutics (NASDAQ:VKTX) StockViking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.Read More Receive VKTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Viking Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VKTX Stock News HeadlinesMarch 28, 2023 | marketbeat.comHere’s Why Viking Therapeutics Rose Over 50% on Obesity Drug DataClinical-stage biotechnology company Viking Therapeutics, Inc. (NASDAQ: VKTX) stock jumped more than 50% on positive Phase 1 data on its novel dual GLP-1/GLPMarch 29, 2023 | msn.comViking Therapeutics proposes stock offering, size not disclosedMarch 29, 2023 | Porter & Company (Ad)Biden's corruption knows no endPorter Stansberry here -- I reveal the shocking changes this Obama policy will usher in… what it means for you, your family, and your finances… and how you can prepare for this new American era. Stream my new documentary at no cost today.March 29, 2023 | msn.comBTIG Maintains Buy Rating for Viking Therapeutics: Here's What You Need To KnowMarch 29, 2023 | finance.yahoo.comViking (VKTX) Announces Clinical Data for Metabolic DisordersMarch 29, 2023 | finance.yahoo.comViking Therapeutics Announces Proposed Public Offering of Common StockMarch 29, 2023 | markets.businessinsider.comViking Therapeutics (VKTX) Receives a Buy from BTIGMarch 28, 2023 | msn.comViking’s stock rallies as it announces trial for oral version of obesity drugMarch 29, 2023 | Porter & Company (Ad)A strange force is brewing…An economic force with the potential to be bigger than the 1880s railroad boom, the 1920s automobile boom, the baby boom of the 1960s, or the Dotcom boom of the ‘90s. And while Biden has nothing to do with it… he’ll take full credit. March 28, 2023 | theglobeandmail.com$VKTX: Viking Therapeutics Started New Bullish CycleMarch 28, 2023 | msn.comHere's Why Viking Therapeutics Rose Over 50% on Obesity Drug DataMarch 28, 2023 | marketwatch.comViking Therapeutics Shares Soar on VK2735 Home-Run Data >VKTXMarch 28, 2023 | proactiveinvestors.comViking Therapeutics shares up more than 50% on positive trial results for obesity drugMarch 28, 2023 | msn.comVKTX Soars on Promising VK2735 DataMarch 28, 2023 | markets.businessinsider.comWhy Viking Therapeutics Stock Is Soaring TuesdayMarch 28, 2023 | marketwatch.comViking Therapeutics Shares Surge Premarket on VK2735 Study Data >VKTXMarch 28, 2023 | markets.businessinsider.comViking Therapeutics: Phase 1 VK2735 Clinical Trial Reports Positive ResultsMarch 28, 2023 | reuters.comViking Therapeutics to start obesity drug mid-stage trialMarch 28, 2023 | seekingalpha.comViking jumps 39% on early-stage data for obesity candidateMarch 27, 2023 | finance.yahoo.comIs Viking Therapeutics a Smart Buy on the Dip?March 21, 2023 | za.investing.comViking Therapeutics sell-off is unwarranted, attractive opportunity to add - TruistMarch 18, 2023 | seekingalpha.comViking Therapeutics: Some Caution WarrantedMarch 18, 2023 | nasdaq.comStifel Initiates Coverage of Viking Therapeutics (VKTX) with Buy RecommendationMarch 17, 2023 | markets.businessinsider.com4 Analysts Have This to Say About Viking TherapeuticsMarch 15, 2023 | finance.yahoo.comWe're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn RateFebruary 23, 2023 | finance.yahoo.com2 Surging Healthcare Stocks That Are Still Worth BuyingFebruary 9, 2023 | finanznachrichten.deViking Therapeutics, Inc.: Viking Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate UpdateSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive VKTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Viking Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VKTX Company Calendar Last Earnings2/08/2023Today3/29/2023Next Earnings (Estimated)4/26/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VKTX CUSIPN/A CIK1607678 Webwww.vikingtherapeutics.com Phone(858) 704-4660FaxN/AEmployees17Year FoundedN/APrice Target and Rating Average Stock Price Forecast$25.89 High Stock Price Forecast$35.00 Low Stock Price Forecast$15.00 Forecasted Upside/Downside+39.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($0.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-68,870,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-42.77% Return on Assets-38.70% Debt Debt-to-Equity RatioN/A Current Ratio7.61 Quick Ratio7.61 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.89 per share Price / Book8.43Miscellaneous Outstanding Shares78,420,000Free Float74,106,000Market Cap$1.25 billion OptionableOptionable Beta0.77 Key ExecutivesBrian LianPresident, Chief Executive Officer & DirectorMarianne ManciniChief Operating OfficerGregory S. ZanteChief Financial OfficerMichael MorneauVice President-Finance & AdministrationKey CompetitorsPharming GroupNASDAQ:PHARCymaBay TherapeuticsNASDAQ:CBAYSeres TherapeuticsNASDAQ:MCRBInnovivaNASDAQ:INVAKiniksa PharmaceuticalsNASDAQ:KNSAView All CompetitorsInstitutional OwnershipChartwell Investment Partners LLCBought 87,842 shares on 2/16/2023Ownership: 0.112%Boothbay Fund Management LLCBought 2,981 shares on 2/15/2023Ownership: 0.068%Jane Street Group LLCBought 37,600 shares on 2/15/2023Ownership: 0.000%Belvedere Trading LLCBought 11,300 shares on 2/15/2023Ownership: 0.000%Steward Partners Investment Advisory LLCBought 10,000 shares on 2/15/2023Ownership: 0.013%View All Institutional Transactions VKTX Stock - Frequently Asked Questions Should I buy or sell Viking Therapeutics stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VKTX shares. View VKTX analyst ratings or view top-rated stocks. What is Viking Therapeutics' stock price forecast for 2023? 8 analysts have issued 12 month price objectives for Viking Therapeutics' shares. Their VKTX share price forecasts range from $15.00 to $35.00. On average, they anticipate the company's share price to reach $25.89 in the next twelve months. This suggests a possible upside of 62.5% from the stock's current price. View analysts price targets for VKTX or view top-rated stocks among Wall Street analysts. How have VKTX shares performed in 2023? Viking Therapeutics' stock was trading at $9.40 on January 1st, 2023. Since then, VKTX stock has increased by 69.5% and is now trading at $15.93. View the best growth stocks for 2023 here. When is Viking Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 26th 2023. View our VKTX earnings forecast. How were Viking Therapeutics' earnings last quarter? Viking Therapeutics, Inc. (NASDAQ:VKTX) issued its earnings results on Wednesday, February, 8th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by $0.03. What ETFs hold Viking Therapeutics' stock? ETFs with the largest weight of Viking Therapeutics (NASDAQ:VKTX) stock in their portfolio include SPDR S&P Biotech ETF (XBI), Invesco DWA SmallCap Momentum ETF (DWAS), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and ALPS Medical Breakthroughs ETF (SBIO).iShares Micro-Cap ETF (IWC) and What other stocks do shareholders of Viking Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Viking Therapeutics investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), SCYNEXIS (SCYX), Amarin (AMRN), Advanced Micro Devices (AMD), Verastem (VSTM), Energy Transfer (ET) and Inovio Pharmaceuticals (INO). When did Viking Therapeutics IPO? (VKTX) raised $20 million in an initial public offering (IPO) on Wednesday, April 29th 2015. The company issued 2,500,000 shares at $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO and Feltl and Company was co-manager. What is Viking Therapeutics' stock symbol? Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX." Who are Viking Therapeutics' major shareholders? Viking Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Boxer Capital LLC (1.96%), Two Sigma Investments LP (1.65%), Point72 Asset Management L.P. (1.44%), Renaissance Technologies LLC (1.24%), Dimensional Fund Advisors LP (1.11%) and Geode Capital Management LLC (0.85%). Insiders that own company stock include Ligand Pharmaceuticals Inc and Matthew W Foehr. View institutional ownership trends. How do I buy shares of Viking Therapeutics? Shares of VKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Viking Therapeutics' stock price today? One share of VKTX stock can currently be purchased for approximately $15.93. How much money does Viking Therapeutics make? Viking Therapeutics (NASDAQ:VKTX) has a market capitalization of $1.25 billion. The biotechnology company earns $-68,870,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. How can I contact Viking Therapeutics? Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The official website for the company is www.vikingtherapeutics.com. The biotechnology company can be reached via phone at (858) 704-4660 or via email at sdiaz@vidasp.com. This page (NASDAQ:VKTX) was last updated on 3/29/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.